Dechra Pharmaceuticals PLC Director/PDMR Shareholding (6428M)
22 Septiembre 2021 - 7:59AM
UK Regulatory
TIDMDPH
RNS Number : 6428M
Dechra Pharmaceuticals PLC
22 September 2021
22 September 2021
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Dechra Pharmaceuticals PLC announces that on 20 September 2021,
the following PDMRs acquired ordinary shares of 1p each in the
Company pursuant to awards granted to them on 26 October 2018 under
the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP).
The vesting of the awards was subject to the achievement of
performance conditions which were satisfied to the extent that the
awards vested at 73.8%. Ian Page and Tony Griffin sold sufficient
of the shares they acquired in order to fund the resulting tax
liability. In accordance with the Company's Directors' Remuneration
Policy, the remaining shares must be retained for a period of two
years from the date of vesting.
Name Capacity Shares Shares Sold Sale Price Total beneficial Percentage
acquired per share shareholding of issued
following this share capital
announcement
Ian Page Director 34,071 16,062 GBP52.365113 358,021 0.331%
Tony Griffin Director 10,659 5,346 GBP52.365113 33,463 0.031%
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the UK Market Abuse
Regulation.
Notification of Dealing Forms
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
---------------------------------- ----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------
a) Position/status Director/PDMR
---------------------------------- ----------------------------------------
b) Initial notification/ Initial Notification
amendment
---------------------------------- ----------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
---------------------------------- ----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
---------------------------------- ----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
---------------------------------- ----------------------------------------
b) Nature of the Acquisition of shares pursuant to the
transaction Company's Long Term Incentive Plan
---------------------------------- ----------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPNil Cost 34,071
---------------------------------- ---------------------- ----------------
d) Aggregated information
* Aggregate volume
N/A
* Price
---------------------------------- ----------------------------------------
e) Date of the transaction 2021.09.20
---------------------------------- ----------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------------- ----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
--------------------------------- ------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Director/PDMR
--------------------------------- ------------------------------------------
b) Initial notification/ Initial Notification
amendment
--------------------------------- ------------------------------------------
3. Details of the Issuer
-----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
--------------------------------- ------------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
--------------------------------- ------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-----------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
--------------------------------- ------------------------------------------
b) Nature of the Partial sale of shares obtained under
transaction the Company's Long Term Incentive Plan
to satisfy tax liability
--------------------------------- ------------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP52.365113 16,062
--------------------------------- ------------------------ ----------------
d) Aggregated information
* Aggregate volume 16,062
GBP52.365113
* Price GBP841,088.45
* Total
--------------------------------- ------------------------------------------
e) Date of the transaction 2021.09.21
--------------------------------- ------------------------------------------
f) Place of the transaction London Stock Exchange
--------------------------------- ------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Tony Griffin
------------------------------------- -------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------------
a) Position/status Director/PDMR
------------------------------------- -------------------------------------------
b) Initial notification/ Initial Notification
amendment
------------------------------------- -------------------------------------------
3. Details of the Issuer
----------------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
------------------------------------- -------------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
------------------------------------- -------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
------------------------------------- -------------------------------------------
b) Nature of the Acquisition of shares pursuant to
transaction the Company's Long Term Incentive Plan
------------------------------------- -------------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBPnil 10,659
------------------------------------- -------------------- ---------------------
d) Aggregated information
* Aggregate volume
N/A
* Price
------------------------------------- -------------------------------------------
e) Date of the transaction 2021.09.20
------------------------------------- -------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------- -------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Tony Griffin
--------------------------------- ------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Director/PDMR
--------------------------------- ------------------------------------------
b) Initial notification/ Initial Notification
amendment
--------------------------------- ------------------------------------------
3. Details of the Issuer
-----------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
--------------------------------- ------------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
--------------------------------- ------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-----------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
--------------------------------- ------------------------------------------
b) Nature of the Partial sale of shares obtained under
transaction the Company's Long Term Incentive Plan
to satisfy tax liability
--------------------------------- ------------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP52.365113 5,346
--------------------------------- ------------------------ ----------------
d) Aggregated information
* Aggregate volume 5,346
GBP52.365113
* Price GBP279,943.89
* Total
--------------------------------- ------------------------------------------
e) Date of the transaction 2021.09.21
--------------------------------- ------------------------------------------
f) Place of the transaction London Stock Exchange
--------------------------------- ------------------------------------------
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBDGDCIUDDGBD
(END) Dow Jones Newswires
September 22, 2021 08:59 ET (12:59 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
